| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Cowealth Medical China Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.41 |
| 52 Week High | CN¥11.30 |
| 52 Week Low | CN¥4.71 |
| Beta | 0.50 |
| 11 Month Change | 3.84% |
| 3 Month Change | -10.73% |
| 1 Year Change | -35.36% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.28% |
Recent News & Updates
Shareholder Returns
| 603122 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 8.9% | -2.9% | -2.8% |
| 1Y | -35.4% | -38.1% | -21.0% |
Return vs Industry: 603122 exceeded the CN Healthcare industry which returned -37.8% over the past year.
Return vs Market: 603122 underperformed the CN Market which returned -20.6% over the past year.
Price Volatility
| 603122 volatility | |
|---|---|
| 603122 Average Weekly Movement | 5.6% |
| Healthcare Industry Average Movement | 5.0% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 603122 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603122's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 240 | Qiongzhi Wang | ch.cowealth.com |
Cowealth Medical China Co.,Ltd. distributes medical products for hospitals in China. The company offers reagents and consumables; in-vitro diagnostic products; and oncology and ophthalmology medical devices.
Cowealth Medical China Co.,Ltd. Fundamentals Summary
| 603122 fundamental statistics | |
|---|---|
| Market cap | CN¥2.15b |
| Earnings (TTM) | CN¥45.10m |
| Revenue (TTM) | CN¥1.06b |
47.8x
P/E Ratio2.0x
P/S RatioIs 603122 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603122 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.06b |
| Cost of Revenue | CN¥844.92m |
| Gross Profit | CN¥219.11m |
| Other Expenses | CN¥174.01m |
| Earnings | CN¥45.10m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 20.59% |
| Net Profit Margin | 4.24% |
| Debt/Equity Ratio | 10.7% |
How did 603122 perform over the long term?
See historical performance and comparison